LNC Therapeutics, a French company specializing in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, raised €6.5 million ($7.7 million) in Series C funding.
In the same category
Seventure Partners : Une croissance continue dans le secteur du microbiome en 2021 qui va se...
Mar 15, 2022
more +